Ovarian Cancer News and Research

Latest Ovarian Cancer News and Research

BioCancell reports results of BC-819 Phase I/IIa clinical trial for pancreatic cancer

Tikcro Technologies Ltd. today announced that BioCancell reported results from a Phase I/IIa clinical trial to establish the safety, optimal dose and preliminary efficacy of BioCancell's lead drug-candidate, BC-819, as a treatment for pancreatic cancer.

3 Nov 2010

Scientists investigate possible link between women's menstrual periods and ovarian cancer

SCIENTISTS in London are investigating a possible link between women's menstrual periods and ovarian cancer.

2 Nov 2010

BioCancell's Phase I/IIa clinical trial of BC-819 shows positive result for pancreatic cancer

BioCancell, a developer of anti-cancer drugs, announced success in attaining the goals of its Phase I/IIa clinical trial of BC-819 as a treatment for pancreatic cancer, which demonstrated an excellent safety profile and preliminary efficacy.

2 Nov 2010

New findings pave way to improve early detection of ovarian cancer

A drug in testing to treat atherosclerosis significantly inhibited growth of ovarian cancer in both human cell lines and mouse models, the first such report of a peptide being used to fight malignancies, according to a study by researchers at UCLA's Jonsson Comprehensive Cancer Center.

2 Nov 2010

Access Pharmaceuticals receives $1.5 million in government grants

ACCESS PHARMACEUTICALS, INC. a biopharmaceutical company leveraging its proprietary drug-delivery platforms to develop treatments in areas of oncology, cancer supportive care and diabetes, announced it has been awarded $1.5 million in government grants.

2 Nov 2010

GOG to initiate combination elesclomol-paclitaxel Phase 2 clinical trial for ovarian cancer

Synta Pharmaceuticals Corp., a biopharmaceutical company focused on discovering, developing, and commercializing small molecule drugs to treat severe medical conditions, today announced that the Gynecologic Oncology Group (GOG) will initiate a Phase 2 clinical trial of elesclomol in combination with paclitaxel for the treatment of persistent or recurrent ovarian, fallopian tube or primary peritoneal cancer.

1 Nov 2010

Merck reports $342 million net income for 2010 third quarter

Merck & Co., Inc. today announced financial results for the third quarter of 2010. The company reported non-GAAP (generally accepted accounting principles) earnings per share (EPS) for the third quarter of $0.85, which excludes purchase accounting adjustments, restructuring costs, merger-related expenses and a $950 million legal reserve.

29 Oct 2010

Study suggests microRNA binding site helps improved prognosis of colorectal cancer at early stage

A variant site linked to poor outcome in advanced colorectal cancer has now been found to predict improved prognosis in early stages of cancer, according to research presented at the American Association for Cancer Research special conference on Colorectal Cancer: Biology to Therapy, held Oct. 27-30, 2010.

29 Oct 2010

ImmunoGen first quarter net loss increases to $12.9 million

ImmunoGen, Inc., a biotechnology company that develops targeted antibody-based anticancer products using its antibody expertise and Targeted Antibody Payload (TAP) technology, today announced financial results for the three-month period ended September 30, 2010 - the first quarter of the Company's 2011 fiscal year (1QFY11).

29 Oct 2010

VCA Clinical Fellowship awarded for epithelial ovarian cancer research

Dr Clare Scott from the Walter and Eliza Hall Institute in Melbourne, Australia, has been awarded a Victorian Cancer Agency (VCA) Clinical Fellowship to further research into an aggressive and highly lethal form of ovarian cancer.

27 Oct 2010

Myriad signs agreement with Abbott for BRACAnalysis test

Myriad Genetics, Inc. today announced that it has signed an agreement with Abbott Laboratories, a global health care company, to conduct BRCA1 and BRCA2 mutation testing on patients to be enrolled in a Phase III multi-center, multi-national clinical study of a novel drug candidate for the treatment of metastatic breast cancer.

27 Oct 2010

ACOG joins Jay Monahan Center to develop new chapter on Female Cancers resource guide

The New York State Chapter of the American Congress of Obstetricians and Gynecologists, District II (ACOG) has partnered with the Jay Monahan Center for Gastrointestinal Health at NewYork-Presbyterian Hospital/Weill Cornell Medical Center to develop the fifth and final chapter to the Focus on Female Cancers resource guide.

22 Oct 2010

Matrix-Bio's VeraMarker-BCR blood test predicts breast cancer recurrence 13 months before clinical diagnosis

Connie Krabbe understands the fear and foreboding breast cancer survivors feel when visiting their physicians for post-treatment check-ups. Two of her four sisters died of metastatic cancer related to breast cancer, enduring bone, brain, and ovarian cancer before succumbing to the disease in their early 50s.

21 Oct 2010

Menopausal estrogen replacement therapy speeds growth of ovarian cancer

Estrogen therapy used by menopausal women causes a type of ovarian cancer to grow five times faster, according to a new study by researchers at the University of Colorado Cancer Center.

21 Oct 2010

Access submits additional patent applications for Cobalamin-mediated oral drug delivery technology

ACCESS PHARMACEUTICALS, INC., a biopharmaceutical company leveraging its proprietary drug-delivery platforms to develop treatments in areas of oncology, cancer supportive care and diabetes, announced it has submitted additional patent applications, covering its Cobalamin-mediated oral drug delivery technology formulations of many global top-100 injectable drugs, as a result of the growing interest surrounding the company's proprietary oral delivery technology.

21 Oct 2010

A universal cancer treatment for a universal cancer marker

A latest study shows that a hormone receptor normally confined to the reproductive organs is found in malignant tumors in many parts of the body. Researchers from the Mt. Sinai School of Medicine in New York City explained that this may mean a new target for the early diagnosis and treatment of cancer. The study was published in the latest issue of The New England Journal of Medicine.

20 Oct 2010

Abbott third quarter worldwide sales increase 11.8% to $8.7 billion

Abbott today announced financial results for the third quarter ended Sept. 30, 2010.

20 Oct 2010

MabCure announces agreement with Europe's medical centers to explore diagnostic test for ovarian cancer

Biotechnology company MabCure, Inc. today announced that it has signed a collaboration agreement with Catholic University, K.U. Leuven and University Hospital, UZ Leuven, Belgium, together comprising one of the largest and most reputable medical centers in Europe.

20 Oct 2010

Researchers to test nanoparticle-based theranostics for pancreatic cancer treatment

Researchers from Rice University's Laboratory for Nanophotonics (LANP), the radiology department at Baylor College of Medicine (BCM) and the University of Texas MD Anderson Cancer Center are preparing to test a combined approach for diagnosing and treating pancreatic cancer with a specially engineered nanoparticle.

19 Oct 2010

St. Joseph's gynecologic oncologist expresses concern about ovarian cancer study

An internationally-recognized gynecologic oncologist at St. Joseph's Hospital and Medical Center in Phoenix, Arizona is warning that the results from a long-awaited global study of ovarian cancer should be viewed cautiously.

18 Oct 2010

Ovarian Cancer News and Research

Latest Ovarian Cancer News and Research

BioCancell reports results of BC-819 Phase I/IIa clinical trial for pancreatic cancer

Scientists investigate possible link between women's menstrual periods and ovarian cancer

BioCancell's Phase I/IIa clinical trial of BC-819 shows positive result for pancreatic cancer

New findings pave way to improve early detection of ovarian cancer

Access Pharmaceuticals receives $1.5 million in government grants

GOG to initiate combination elesclomol-paclitaxel Phase 2 clinical trial for ovarian cancer

Merck reports $342 million net income for 2010 third quarter

Study suggests microRNA binding site helps improved prognosis of colorectal cancer at early stage

ImmunoGen first quarter net loss increases to $12.9 million

VCA Clinical Fellowship awarded for epithelial ovarian cancer research

Myriad signs agreement with Abbott for BRACAnalysis test

ACOG joins Jay Monahan Center to develop new chapter on Female Cancers resource guide

Matrix-Bio's VeraMarker-BCR blood test predicts breast cancer recurrence 13 months before clinical diagnosis

Menopausal estrogen replacement therapy speeds growth of ovarian cancer

Access submits additional patent applications for Cobalamin-mediated oral drug delivery technology

A universal cancer treatment for a universal cancer marker

Abbott third quarter worldwide sales increase 11.8% to $8.7 billion

MabCure announces agreement with Europe's medical centers to explore diagnostic test for ovarian cancer

Researchers to test nanoparticle-based theranostics for pancreatic cancer treatment

St. Joseph's gynecologic oncologist expresses concern about ovarian cancer study

Clue's CEO Rhiannon White on the Future of Femtech and PCOS

Freezing Point Osmometry in Life Science Applications

Precision in every drop: Inside Hamilton’s syringe technology

Ovarian Cancer News and Research

Latest Ovarian Cancer News and Research

Clue's CEO Rhiannon White on the Future of Femtech and PCOS

Freezing Point Osmometry in Life Science Applications

Precision in every drop: Inside Hamilton’s syringe technology

Newsletters you may be interested in